Quarterly report pursuant to Section 13 or 15(d)

OPERATING SEGMENTS - Narrative (Details)

v3.23.3
OPERATING SEGMENTS - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 29, 2023
Sep. 30, 2022
Sep. 29, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]        
Tax litigation expense $ 1   $ 7  
Our proportionate share of unusual or infrequent items charge/(gain) recorded by equity method investees 48 $ 14 132 $ 44
Equity Method Investment, Other than Temporary Impairment       96
Gain (Loss) on Sale of Previously Unissued Stock by Equity Investee       (24)
Asset Impairment Charges   57 25 57
Productivity and Reinvestment        
Segment Reporting Information [Line Items]        
Productivity, integration and restructuring initiatives 58 27 109 56
BodyArmor        
Segment Reporting Information [Line Items]        
Gain (loss) related to BodyArmor transaction (4) (15) (11) (23)
Europe, Middle East & Africa        
Segment Reporting Information [Line Items]        
Equity Method Investment, Other than Temporary Impairment       96
North America        
Segment Reporting Information [Line Items]        
Productivity, integration and restructuring initiatives     26  
Business Exit Costs 4 8 15 31
North America | Operating Income (Loss)        
Segment Reporting Information [Line Items]        
Business Exit Costs       30
North America | Productivity and Reinvestment        
Segment Reporting Information [Line Items]        
Refinement of previously established accruals     (1)  
North America | BodyArmor        
Segment Reporting Information [Line Items]        
Gain (loss) related to BodyArmor transaction       21
Asia Pacific        
Segment Reporting Information [Line Items]        
Business Exit Costs     35  
Our proportionate share of unusual or infrequent items charge/(gain) recorded by equity method investees 6   146  
Asset Impairment Charges   57   57
Bottling investments        
Segment Reporting Information [Line Items]        
Our proportionate share of unusual or infrequent items charge/(gain) recorded by equity method investees 42 14 (14) 44
Corporate        
Segment Reporting Information [Line Items]        
Tax litigation expense     7  
Debt and Equity Securities, Gain (Loss) (119) (78) 121 (449)
Gain (Loss) on Disposition of Business     439  
Gain (Loss) on Sale of Previously Unissued Stock by Equity Investee       (24)
Corporate | Productivity and Reinvestment        
Segment Reporting Information [Line Items]        
Productivity, integration and restructuring initiatives 58 27 110 56
Corporate | fairlife        
Segment Reporting Information [Line Items]        
Contingent Consideration Liability 296 32 1,620 971
Corporate | BodyArmor        
Segment Reporting Information [Line Items]        
Gain (loss) related to BodyArmor transaction $ (4) $ (15) $ (11) $ (44)